Bone marrow disorder
MONDO:0003225Any disease of the bone marrow.
Also known as: bone marrow disease, bone marrow disease or disorder, bone marrow disorder, disease of bone marrow, disease or disorder of bone marrow, disorder of bone marrow
1761 clinical trials for this condition and its sub-types, 18 tagged with Bone marrow disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Bone marrow disorder
-
Bone marrow neoplasm 3 trials · 1,631 incl. sub-types
1 sub-type
- Bone marrow cancer 2 trials · 1,631 incl. sub-types Sub-types →
-
Polycythemia 9 trials · 99 incl. sub-types
5 sub-types
- Familial polycythemia 1 trial · 92 incl. sub-types Sub-types →
- Secondary polycythemia 2 trials Sub-types →
- Acquired polycythemia 0 trials Sub-types →
- Physiological polycythemia 0 trials
- Polycythemia neonatorum 0 trials
-
Bone marrow failure syndrome 48 trials
8 sub-types
- AMED syndrome, digenic 0 trials
- Ziegler-Huang syndrome 0 trials
- Autosomal dominant aplasia and myelodysplasia 0 trials
- Bone marrow failure syndrome 3 0 trials
- Bone marrow failure syndrome 4 0 trials
- Bone marrow failure syndrome 5 0 trials
- Bone marrow failure syndrome 6 0 trials
- Pancytopenia-developmental delay syndrome 0 trials
-
Osteomyelitis 43 trials · 46 incl. sub-types
2 sub-types
- Chronic recurrent multifocal osteomyelitis 3 trials · 4 incl. sub-types Sub-types →
- Petrositis 0 trials
-
Fanconi anemia 29 trials · 42 incl. sub-types
22 sub-types
- Fanconi anemia complementation group D1 6 trials
- Fanconi anemia complementation group A 4 trials
- Fanconi anemia complementation group E 4 trials
- Fanconi anemia complementation group N 2 trials
- Fanconi anemia, complementation group S 2 trials
- Fanconi anemia complementation group B 0 trials
- Fanconi anemia complementation group C 0 trials
- Fanconi anemia complementation group D2 0 trials
- Fanconi anemia complementation group F 0 trials
- Fanconi anemia complementation group G 0 trials
- Fanconi anemia complementation group I 0 trials
- Fanconi anemia complementation group J 0 trials
- Fanconi anemia complementation group L 0 trials
- Fanconi anemia complementation group O 0 trials
- Fanconi anemia complementation group P 0 trials
- Fanconi anemia complementation group Q 0 trials
- Fanconi anemia complementation group R 0 trials
- Fanconi anemia complementation group T 0 trials
- Fanconi anemia complementation group U 0 trials
- Fanconi anemia complementation group V 0 trials
- Fanconi anemia, complementation group W 0 trials
- Fanconi anemia, complementation group 10 0 trials
-
Drachtman Weinblatt Sitarz syndrome 0 trials
-
Premature ovarian failure 15 0 trials
Most studied deeper sub-types
-
New hope for anemia patients: drug may cut need for blood transfusions
Disease control OngoingThis study tests a drug called luspatercept in people with anemia caused by myelodysplastic syndromes (MDS) or beta-thalassemia who need regular blood transfusions. The goal is to see if the drug is safe and can reduce the number of transfusions needed. About 85 participants in I…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control CancelledThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase 1/2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for myelofibrosis patients with dangerous low platelet counts
Disease control OngoingThis phase 3 study tests a drug called pacritinib against standard treatments chosen by the doctor in people with myelofibrosis who have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and reduce symptoms like tiredness, pain, and i…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Scientists unravel genetic secrets of bone marrow failure
Knowledge-focused By invitation onlyThis study aims to understand the genetic and molecular changes in people with bone marrow failure disorders. Researchers will analyze blood and bone marrow samples from up to 1,400 participants to track how these changes evolve over time. The goal is to better predict disease ou…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC